SEC Form 4 · accession 0001209191-16-111237
Aimmune Therapeutics, Inc. · AIMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Patrick G Enright
Director · 10% Owner
Period of report
Mar 29, 2016
Accepted (ET)
Mar 31, 2016 · 5:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1,F2 | Mar 29, 2016 | P | 33,064 | $13.4986 | A | 7,467,694 | I | By Longitude Venture Partners II, L.P. |
| Common Stock, $0.0001 par valueF3,F2 | Mar 29, 2016 | P | 45,440 | $14.1465 | A | 7,513,134 | I | By Longitude Venture Partners II, L.P. |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $12.90 to $13.89. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.
- F2The shares are held by Longitude Venture Partners II, L.P. ("Longitude Venture II"). Longitude Capital Partners II, LLC ("Longitude Capital II") is the general partner of Longitude Venture II and may be deemed to have sole voting, investment and dispositive power over the shares held by Longitude Venture II. Patrick G. Enright is a managing member of Longitude Capital II and in his capacity as such may be deemed to exercise shared voting and investment power over the shares held by Longitude Venture II. Mr. Enright disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
- F3Reflects purchases of ordinary shares executed in multiple transactions at prices ranging from $13.90 to $14.29. The price reported reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the purchases were effected.